Business Description
Eledon Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 156.07 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 46.1 | |||||
3-Year EPS without NRI Growth Rate | 51.3 | |||||
3-Year FCF Growth Rate | 46.5 | |||||
3-Year Book Growth Rate | -71.3 | |||||
Future 3-5Y EPS without NRI Growth Rate | 19.67 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.36 | |||||
9-Day RSI | 38.6 | |||||
14-Day RSI | 46.71 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.53 | |||||
Quick Ratio | 6.53 | |||||
Cash Ratio | 6.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.9 | |||||
Shareholder Yield % | -20.86 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -44.97 | |||||
ROA % | -21.62 | |||||
ROIC % | -158.52 | |||||
ROC (Joel Greenblatt) % | -4903.96 | |||||
ROCE % | -59.62 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.31 | |||||
Price-to-Tangible-Book | 4.04 | |||||
EV-to-EBIT | -3.07 | |||||
EV-to-EBITDA | -3.09 | |||||
EV-to-FCF | -4.61 | |||||
Price-to-Net-Current-Asset-Value | 4.12 | |||||
Price-to-Net-Cash | 4.44 | |||||
Earnings Yield (Greenblatt) % | -32.57 | |||||
FCF Yield % | -14.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Eledon Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.862 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 46.71 | ||
14-Day ATR (€) | 0.146818 | ||
20-Day SMA (€) | 4.149 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 2.551 - 4.78 | ||
Shares Outstanding (Mil) | 59.74 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Eledon Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Eledon Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Eledon Pharmaceuticals Inc Frequently Asked Questions
What is Eledon Pharmaceuticals Inc(STU:2TK)'s stock price today?
When is next earnings date of Eledon Pharmaceuticals Inc(STU:2TK)?
Does Eledon Pharmaceuticals Inc(STU:2TK) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |